Dermatology Innovation Forum 2023

Biography

Dr. Kelly Collins is the Global Director of Digital Adherence at Dimagi, Inc. An infectious disease epidemiologist by training, Dr. Collins obtained her PhD in Global Public Health from the University California San Diego, and her MPH in Epidemiology from San Diego State University. Dr. Collins is the former CEO and Co-Founder of SureAdhere Mobile Technology, a UC San Diego spinout acquired by Dimagi in February 2022. As a social entrepreneur, Dr. Collins’ career mission has been to support the scale of evidence-based, high-impact digital health interventions globally. Dr. Collins’ 12+ years of evaluating digital adherence interventions across five continents and 25 countries has resulted in 29 peer reviewed publications on the topic, nine of which she co-authored. Additionally, Dr. Collins led SureAdhere while the company supported two randomized controlled trials evaluating video observed therapy for TB treatment adherence. Trial outcomes were published in the Lancet and JAMA Open, and data from both studies informed WHO and CDC treatment guidelines for TB in 2017 and 2022. Since 2018, Dr. Collins’s team has focused their efforts on expanding the use of SureAdhere outside of TB to new use cases including treatment adherence for therapeutic drug trials and medication assisted therapy for opioid use disorder.

Biography

Mr. du Crest is a skin addict! He is the founder of SkinAid a skin centric consulting and media company dedicated to dermatology, aesthetic dermatology, skincare and home-use devices. He is also the co-founder of the IMCAS Innovation Tank and co-founder of the Skin & Digital Summit whose vision is to create and facilitate a comprehensive conversation about what advances in digital technology & artificial intelligence can bring to the Skin Business at large (dermatology, aesthetics, skincare). Previously, Mr. du Crest spent twelve years at Grey Healthcare (healthcare communication agency) and thirteen years at L’Oréal.

Biography

Dr. Feldman is Professor of Dermatology, Pathology, Social Sciences & Health Policy, and Molecular Medicine & Translational Science at the Wake Forest University School of Medicine.   He leads the Center for Dermatology Research, a health services research center whose mission is to improve the care of patients with skin disease.  Dr. Feldman’s chief clinical interest is psoriasis, a physically & psychosocially disabling chronic disease.  His passion is to help guide how patients with psoriasis are treated.  He serves on the Medical Board of the National Psoriasis Foundation and directed psoriasis education programs for the American Academy of Dermatology.  According to Expertscape.com, Feldman has been rated among the top experts in the world on psoriasis, dermatology, and, most importantly, treatment adherence.

Feldman’s research has been published in over 1,000 Medline-referenced articles. In collaboration with other investigators, Feldman has done groundbreaking work on patients’ adherence to their medication treatment regimens, transforming how physicians understand and enhance patients’ use of treatment for chronic skin diseases.  He has published regular columns on patient adherence in PM360: The Essential Resource for Pharma Marketers and in the primary care journal Consultant360, and he is author of the book Practical Ways to Improve Patients’ Treatment Outcomes.  Since 2021, Feldman has served as Senior Advisor for Dermatology & Patient Adherence to Sensal Health, based in Chapel Hill, developing, testing, and implementing novel sensor-based technologies for assessing and improving patients’ adherence to treatment.

Biography

Dr. Garibyan is a physician-scientist and faculty member at Harvard Medical School, an internationally renowned speaker, and a humanitarian. She is listed as an inventor on 15 pending and granted patents in fields of medical devices, immunology, dermatology, cardiology, and medical innovation. Her research focuses on innovative biomedical translational discoveries aimed at identifying unmet medical needs and working with multidisciplinary teams to develop novel treatments. She used this same approach to pioneer injectable cooling devices for aesthetic and medical application since 2012. Several of her inventions have been licensed and led to venture-backed startup companies. She is the co-founder of two startup biotech companies which have resulted from her research discoveries. She serves on several scientific advisory boards for startup companies.

Dr. Garibyan is the co-founder and the Director of the “Magic Wand Initiative” and the Virtual Magic Wand programs, which teach the process of innovation. These internationally recognized programs empower, engage, and teach professionals on how to identify unmet needs and collaborate to identify and implement solutions to problems.

As a humanitarian, Dr. Garibyan has pioneered and established sustainable, medical laser clinics in Armenia for effective treatments of scars and vascular anomalies. Her team has taken several lasers to Armenia and has trained Armenian physicians on the use of laser technology to treat life altering skin diseases. Dr. Garibyan recently founded and serves as the President of a nonprofit organization called “Face of Angel” to continue the mission of this humanitarian work.

Dr. Garibyan received her B.S. summa cum laude from University of California Los Angeles, her M.D. from Harvard Medical School and her Ph.D. from Harvard University in Experimental Pathology/Immunology.

Biography

Michael Girardi graduated magna cum laude from Brown University with a dual degree in Biology and Computer Science and with MD Honors from the Yale School of Medicine, and is now the Robert S. Evans Professor, Vice Chair, and Residency Program Director for the Department of Dermatology; Co-Director of the Yale Cutaneous Lymphoma Group and former Co-Director for the Immunology and Immunotherapy Program for the Yale Comprehensive Cancer Center; and Medical Director of the Extracorporeal Photopheresis and Phototherapy Centers for Yale-New Haven Hospital. Dr. Girardi has led a highly collaborative NIH-funded research program for 20+ years investigating cutaneous immunology, cutaneous carcinogenesis, and cutaneous lymphoma, with over 150 publications and over 10,000 citations. His laboratory was the first to identify the anti-tumor capacity of gamma-delta T cells (and was recognized for this in 2018 by the Journal of Immunology as a “Pillar of Immunology”), to reveal the pro-mutagenic and tumor promoting effects of skin Langerhans cells (published in Science and PNAS), to reveal the coordinated and differential effects of alpha-beta and gamma-delta T cells on skin inflammation and cancer development (published in a series in J Exp Med), and discover novel drug combinations in the treatment of cutaneous lymphoma (published in Blood). Dr. Girardi also serves as a Director for the NIAMS T32 “Yale Investigative Dermatology Training” grant, one of the longest standing dermatology T32s in the country, and he has mentor over 25 pre-doctoral fellows (including 2 Howard Hughes Fellowship recipients, and 4 Yale School of Medicine Thesis Award Recipients) and 12 postdoctoral research fellows, almost all of whom are now full-time academicians in our specialty. Dr. Girardi was elected to the American Society for Clinical Investigation, and awarded the Blavatnik Innovation Award at Yale, the Zeligman Lectureship Award at Johns Hopkins, and the Duhring lectureship award at the University of Pennyslvania. Dr. Girardi is the holder of 10 biomedical patents, and co-founder of two Yale start-up companies.

Biography

Dr. Gwillim completed his medical training at the University of Illinois followed by general surgery training with the Metropolitan Group Hospitals Residency in Chicago. After two years he pivoted from surgery and worked on developing innovative solutions to complex medical problems and gained three years of dermatology clinical trial research experience; one year at Northwestern University and two years at the University of Miami serving as sub-investigator on multiple Phase II and III trials. Currently, a PGY3 dermatology resident with Jackson Memorial Hospital/University of Miami Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, he is serving as Co-Chair of the Surgical Curriculum Reform Committee. Dr. Gwillim is passionate about discovering solutions for medical/surgical practice gaps and creating transformative digital communication platforms that promote enhanced learning and optimize the patient care experience. Through the support of the Magic Wand Initiative, his research and product development efforts have employed a problem-based innovation approach to identify and solve unmet patient needs.

Biography

Emma Guttman-Yassky, MD, PhD is the system chair of the department of dermatology, and the Waldman Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, New York. She is also the director of the center for excellence in eczema and the laboratory for inflammatory skin diseases. She earned her M.D. from Sackler School of Medicine at the Tel-Aviv University, and a Ph.D. degree from the Bar-Ilan University, Israel. After her Israeli Board certification
in dermatology in Israel, Dr. Guttman moved to the U.S. to pursue a two-year postdoctoral fellowship at The Rockefeller University in the Laboratory for Investigative Dermatology. Upon completion of her fellowship, she became board-certified by the American Board of dermatology after a second dermatology residency training at Weill- Cornell Medical College, in NY. Dr. Guttman’s major research focus areas are atopic dermatitis (AD)/eczema and alopecia areata. Her research made paradigm-shifting discoveries on the immunologic basis of AD/eczema in adults and children with atopic dermatitis, enriching the understanding of the pathophysiology of this common disorder, opening the door for novel, pathway-specific drugs in this disease. Recently, Dr. Guttman extended her research interest to hair loss disorders such as alopecia areata and scarring hair loss disorders, chronic hand eczema, keloids, ichtyosis, and other skin diseases, in which her findings are also translated to novel therapeutics. Dr. Guttman co-founded the international eczema council (IEC) and is its immediate past president. Dr. Guttman received many national and international awards (e.g the AAAAI Award for Scientific Innovation and for pioneering discoveries, AAD Young Investigator award, etc). She was elected as a member to the American Society for Clinical Investigation/ASCI, and the American Dermatological Society/ADA. Dr. Gutman is often a keynote and plenary speaker in international and national meetings and authored >300 peer-reviewed publications.

Biography

Dr. Harris is Chair of Dermatology, Director of the Autoimmune Therapeutics Institute, and Director of the Vitiligo Clinic and Research Center at UMass Chan Medical School. He is a dermatologist and physician-scientist, caring for patients in a vitiligo specialty clinic and running a research laboratory focused on understanding disease pathogenesis and developing new treatments. His group integrates basic, translational, and clinical research strategies to accomplish this. As a result, clinical trials in vitiligo have shown success. Dr. Harris founded Villaris Therapeutics (acquired by Incyte in 2022) and 3 other companies to develop treatments for inflammatory skin diseases.

Biography

Dr. Klekotka is a board-certified dermatologist and physician-scientist with extensive early phase and late phase clinical development experience. He has more than 10 years of industry experience in all phases of clinical drug development and life cycle management in dermatology, pulmonology, gastroenterology and rheumatology. Currently, he is at Eli Lilly in San Diego where he leads the early phase immunology clinical group.

Biography

Dr. Ko is Chief of Medical Dermatology at Stanford and spearheads the dermatology department’s efforts around digital health, quality and value-based care. He is active in a number of leadership roles within Stanford Medicine including as an Associate Chief Quality Officer and physician lead of Patient Experience. His passion for innovating on models of care delivery drives his clinical and research efforts around layering advances in artificial intelligence on remote care capabilities to enhance access, quality and value of dermatologic care.

Biography

Dr. Paul F. Lizzul, a physician scientist and entrepreneur, is the Chief Medical Officer of AnaptysBio, focused on delivering innovative immunology therapeutics to patients. Dr Lizzul leads the company’s comprehensive development organization, spanning clinical development, translational medicine, clinical operations, regulatory affairs, data sciences, medical affairs, clinical pharmacology and toxicology. Prior to joining AnaptysBio, he held positions in diverse organizations including Global Development Lead for Inflammation at Amgen, Chief Medical Officer of Sienna Biopharmaceuticals and Senior Medical Director at Kythera Biopharmaceuticals. Dr. Lizzul is also a volunteer faculty member in the division of dermatology at the David Geffen School of Medicine at UCLA. Prior to transitioning into biotech leadership roles Dr. Lizzul was an Assistant Professor of Dermatology and Associate Director of Clinical Research at the Tufts Medical Center. He is a board-certified dermatologist, a faculty member of the American Academy of Dermatology and has also served on the United States Food and Drug Administration (FDA) Dermatology and Ophthalmic Drugs Advisory Committee. Dr. Lizzul received his M.D., Ph.D. in molecular genetics and M.P.H. in epidemiology from the Robert Wood Johnson Medical School at Rutgers. He has also earned an M.B.A. in entrepreneurship from the Rutgers Business School.

Biography

Dr. Luke is a Supervisory Physician and Director of the Division of Therapeutic Performance (DTP1) in the Office of Research and Standards, Office of Generic Drugs at FDA. DTP1 is responsible for facilitating pre-application development of generic drugs by conducting and promoting regulatory science research to establish standards to ensure therapeutic equivalence of new generic drug products. Markham has an MD and a PhD in Pharmacology from Johns Hopkins University and is a dermatologist by training. Markham has research interests in dermatopharmacology, clinical pharmacology, clinical study design and endpoints assessment (including patient-reported outcomes) for medical, surgical, and aesthetic products and serves as consultant dermatologist to various parts of FDA. Markham has been at FDA since 1998 serving various roles, including as the Lead Medical Officer for dermatology drugs, Chief Medical Officer and Deputy Director for the Office of Device Evaluation in the Center for Devices and Radiologic Health, and as Acting Director for Cosmetics in the Center for Food Safety and Applied Nutrition. In each of these roles including his current one, Markham has been involved in programs and initiatives dealing with product innovation as related to Public Health for our nation.

Biography

Dr. Nalamothu is the Founder, Executive Chairman & CSO of Tergus Pharma, a North Carolina-based CDMO which specializes in complete topical drug product development services, skin permeation, in vitro testing, and commercial GMP manufacturing. Dr. Nalamothu earned his Ph.D. in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy. His efforts over the past 26 years in various dermatological companies have led to many commercial products in the market today. He has successfully taken Tergus Pharma from a small R&D facility to a 100,000 SFT commercial manufacturing facility with industry-leading capacities. His knowledge of the unmet needs in the Dermatology CDMO industry led to equipping Tergus Pharma with unique R&D capabilities such as Skin Biology and In Vitro Permeation (IVRT & IVPT) as well as Hormone and High Potent compound manufacturing at a commercial scale. Dr. Nalamothu draws from his exceptional background that combines scientific study with pragmatic, hands-on experience to solve R&D challenges and his ability to translate a concept into a commercial product. He has co/authored numerous publications and has patents for a few of his inventions. He serves as a member of various pharmaceutical associations as well as sits on the boards of various pharmaceutical companies. In his spare time, Dr. Nalamothu enjoys his quiet time with family and boating on Raleigh’s Falls Lake.

Biography

Dr. Odell completed undergraduate education at Cornell University followed by MD and PhD degrees at the University of Vermont. He completed medical residency in dermatology and post-doctoral research under the mentorship of Richard Flavell, PhD, FRS at Yale University, where he was appointed to Assistant Professor in the department of dermatology.

Dr. Odell’s main research interests involve understanding the cellular processes that drive human fibrotic diseases and development of novel therapeutics. In his post-doctoral and young faculty work, Dr. Odell’s studies focused on translational and mouse experiments to understand how immune cells regulate the pathogenesis of fibrosis in patients with scleroderma.

In his principal project, Dr. Odell identified a multicellular signaling circuit that is activated in scleroderma skin and lung fibrosis.

Dr. Odell’s scientific expertise in scleroderma is paired by his clinical activities, where he has a dedicated outpatient fibrosis clinic, is the dermatology leader of the Yale Scleroderma Program, and helps direct the photopheresis unit that includes treatment of patients with scleroderma and chronic GvHD.

Biography

Dr. Papier is a founder of VisualDx and CEO. A dermatologist, Art has a particular interest in designing clinical systems that leverage the human ability for pattern recognition, thereby increasing clinical accuracy and reducing diagnostic error at the point of care. In line with this goal, he has led the development of VisualDx, the first diagnostic clinical decision support system to be widely used, and to incorporate machine learning for skin rashes and lesions. Art is also passionate about the engagement of people in their medical decisions, in consumer health, and developing tools to educate and empower patients in their homes and on their mobile devices. The focus of his work is to assist medical decisions by professionals and people alike, with decision support and AI augmenting human intelligence.
A graduate of Wesleyan University, Art received his MD from the University of Vermont College of Medicine, and completed his graduate medical training at the University of Rochester Medical Center. He is also an Associate Professor of Dermatology and Medical Informatics at the University of Rochester School of Medicine and Dentistry.

Biography

Dr. Payne is a Professor of Dermatology and Director of the Penn Clinical Autoimmunity Center of Excellence at the University of Pennsylvania. Her clinical and research expertise centers on the diagnosis and treatment of autoimmunity. Dr. Payne’s laboratory invented an approach for targeted therapy of autoantibody-mediated diseases known as chimeric autoantibody receptor T cells (CAART), which aims to achieve antigen-specific B cell depletion for safe and durable autoimmune disease remission. Her laboratory performed key studies leading to FDA clearance of the Investigational New Drug applications for DSG3-CAART and MuSK-CAART, the first precision cellular immunotherapies to enter clinical trials for the autoimmune diseases mucosal pemphigus vulgaris and MuSK myasthenia gravis. Outside of Penn, Dr. Payne serves as Vice President of the Society for Investigative Dermatology, chair of the NIAMS Board of Scientific Counselors, and co-founder and co-chair of the Scientific Advisory Board of Cabaletta Bio, a biotechnology company focused on targeted cellular immunotherapies for B cell-mediated diseases.

Biography

Dr. Raff is a physician-scientist, drug developer, and board-certified dermatologist. He is a Senior Medical Director in Clinical Development at EQRx working to develop innovative medicines within inflammation and immunology. Dr. Raff previously served as the Director of Translational Medicine at LEO Pharma. He is an Instructor at Harvard Medical School and maintains a clinical dermatology practice at Beth Israel Lahey Health. He previously worked at the Massachusetts General Hospital and the Wellman Center for Photomedicine. He received his MD/PhD at the University of Southern California, completed his dermatology residency at Harvard, and his post-doctoral fellowship as an NIH-funded T32 fellow under R. Rox Anderson MD at the Wellman Center for Photomedicine. Dr. Raff is a member of the AID Research Leadership Council, was a founding member of the AID Education Committee, and previously served as AID Education Committee Chair, Virtual Magic Wand Co-Chair, and Director of the Hacking Dermatology Initiative.

Biography

Dr. Rubenstein currently serves as Chief Scientific Officer for Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. Dr. Rubenstein joined Dermavant in March 2018 from GlaxoSmithKline Dermatology where he had built an industry-leading dermatology drug development organization as Vice President, Discovery and Preclinical Development. Prior to GSK, Dr. Rubenstein held academic roles at the University of North Carolina at Chapel Hill, most recently serving as the Louis C. Skinner Jr. Distinguished Professor of Dermatology. He is a board-certified dermatologist.

Biography

Dr. Semenov is an Assistant Professor in Dermatology and co-Director of the Oncodermatology Program at the Massachusetts General Hospital and Harvard Medical School, with extensive experience in clinical informatics, health economics, and public health research. He received his bachelor’s in Applied Mathematics & Statistics, master’s in Applied Economics, and medical degrees from Johns Hopkins University and completed residency training in Dermatology at Washington University School of Medicine. Dr. Semenov’s clinical expertise includes cutaneous oncology with a focus on melanoma and supportive oncodermatology. He is the Principal Investigator of the Dermatology Clinical Informatics Laboratory and an Investigator in the Lab of Systems Pharmacology within Harvard Medical School’s Program in Therapeutic Sciences. His laboratory focuses on leveraging large multi-institutional and population-level data to develop precision medicine tools at the interface of dermatology, oncology, and computational biology. Specifically, his research integrates multi-modal clinical, genomic, digital imaging, and molecular data from patients and tumor samples in developing algorithms and clinical decision support models in cutaneous oncology. As part of this work Dr. Semenov’s group has been developing computational approaches for the analysis of digital histopathology and highly multiplexed images using cyclic immunofluorescence. Additionally, as a member of the Severe Immunotherapy Complications service at the Massachusetts General Hospital, Dr. Semenov has developed the largest multi-institutional clinical registry and biorepository for the study of immunotherapy toxicities in the United States.

Biography

Dr. Srivastava is Senior Vice President, Clinical Development at Nimbus Therapeutics. His group has led the clinical development of internally developed, novel small molecules including NDI-034858, an inhibitor of tyrosine kinase 2 (TYK2) in Phase 2b trials for psoriasis and psoriatic arthritis, and NDI-101150, an inhibitor of hematopoietic progenitor kinase 1 (HPK1) in a Phase 1/2 trial in patients with solid tumors.

Prior to joining Nimbus, Bhaskar was Senior Director of Translational Science and Medicine in Immunology at Janssen Research & Development, where he led a group of physician-scientists responsible for the strategy, design, and execution of early phase clinical programs across indications in dermatology and rheumatology. He also played a key role in the founding of Janssen’s Immunodermatology Disease Area Stronghold. Prior to his R&D role, he was Director of Medical Affairs in Dermatology at Janssen, where he served as the U.S. medical lead for the launch of an important psoriasis treatment and the study-responsible physician for the PSOLAR psoriasis registry. A board-certified dermatologist, he spent five years in clinical practice and was Assistant Professor of Dermatology at Yale School of Medicine. He has published extensively in high-impact journals including The Journal of Experimental Medicine, Journal of the American Academy of Dermatology, and the New England Journal of Medicine.

Bhaskar earned his Bachelor of Arts degree in Biochemistry from Harvard University and his M.D. and Ph.D. in Immunology from the University of Pennsylvania School of Medicine. He completed his clinical training in dermatology at the Yale University School of Medicine.

Biography

Dr. Andrew Tadros was born and raised in New Jersey. He completed his undergraduate degree in chemical engineering at Lehigh University (Bethlehem, PA), and he subsequently worked as a research engineer at DuPont (Wilmington, DE). While at DuPont, he conducted research on novel polymer materials for sustainability and national defense applications. He decided to pursue his Engineering PhD at Georgia Tech under the guidance of Dr. Mark Prausnitz, where he leveraged his skills to conduct translational research in minimally invasive medical devices for diagnostic and drug delivery applications within dermatology. While at Georgia Tech he invented a platform drug delivery technology that was patented and is now being licensed by three startup companies that he co-founded. Together these companies have secured over $40M in venture capital funding. Dr. Tadros also holds a medical degree from Emory University (Atlanta, GA), and will be joining the dermatology residency program at Johns Hopkins University (Baltimore, MD). Dr. Tadros is deeply passionate in serving marginalized patients through clinical care and medical innovation. In his free time, he continues to advise the start-up companies that he co-founded. He also has a daily meditation practice, enjoys running, visiting state and national parks, and photography.

Biography

Dr. Vesely is an Assistant Professor in Dermatology at Yale School of Medicine with research training in immunology and clinical expertise in chronic inflammatory skin diseases and cancer immunotherapy. He completed his MD and PhD degrees at Washington University in St. Louis before completing his dermatology residency at Yale School of Medicine. During his post-doctoral fellowship with Dr. Lieping Chen at Yale, Dr. Vesely investigated immune inhibitory receptor V-domain Ig suppressor of T cell activation (VISTA) as a potential therapeutic target for cutaneous lupus. His research program uses spatial proteomics and spatial transcriptomics to visualize the immunopathogenesis of autoimmune skin diseases with a particular emphasis on immune inhibitory receptors that may be stimulated for future autoimmune disease therapy.

Biography

Dr. Xu is a physician-engineer, board certified dermatologist, academic, and entrepreneur. He holds an appointment as the Director of Medical Research at the Querrey Simpson Institute for Bioelectronics at Northwestern University, and the Ruth K. Freinkel, MD, Professorship in the Department of Dermatology at Northwestern University. Dr. Xu has authored more than 120 peer-reviewed publications, which include works in Nature, Science, The New England Journal of Medicine, and the Proceedings of the National Academy of Sciences. Furthermore, he is an inventor on 15 pending and granted patents in the fields of digital health, medical device development, and medical innovation as an MIT 35 Under 35 honoree (Class of 2022). He is currently on leave from his academic position at Northwestern University to serve as the CEO of Sibel Health where he is also a cofounder and board member. To date, Sibel has raised more than $50 million USDs, launched ICU-grade wearable sensors in more than 20 countries, and monitored more than 12,000 individuals with a focus on maternal and neonatal health.

Biography

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.

Biography

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.

Biography

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Biography

Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Biography

Qing Yu Christina Weng is a physician-scientist, entrepreneur, and biotech executive. She is currently the Medical Director of Kira Pharmaceuticals, a Boston-based global biotech company developing innovative complement therapeutics. Christina co-founded Mymiel, a high-performance clean skincare line, where she serves as Chief Strategy Officer. As an Instructor in Dermatology at Harvard Medical School and attending dermatologist at the Massachusetts General Hospital (MGH), she specializes in melanoma and pigmentary disorders.

Christina attended the California Institute of Technology, where she received her bachelor’s degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a medical fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral research was at the Cutaneous Biology Research Center of MGH.

Christina’s bench research has focused on melanocyte biology and mechanisms leading to pigment dysregulation, with an emphasis on clinically translatable opportunities in pigmentary disorders and melanoma. Her work additionally explores strategies for cutaneous drug delivery. Christina’s clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research support and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health.